Liraglutide, a GLP-1 receptor agonist medication that first won FDA approval in 2010, may reduce cognitive impairment in Alzheimer’s patients. It remains to be seen whether semaglutide, liraglutide, or other GLP-1 receptor agonist drugs, will receive FDA approval for the treatment of AD. Novo Nordisk announced in 2020 that an oral formulation of semaglutide would enter phase 3 development for Alzheimer’s disease. In humans, there is evidence suggesting that type 2 diabetes is a risk factor for cognitive decline, but GLP-1 receptor agonists, like semaglutide, can potentially mitigate this risk in people with type 2 diabetes. Unlike Kisunla, however, GLP-1 receptor antagonists do not carry the potential side effect of brain bleeds or swelling.

Source: CNN August 08, 2024 09:47 UTC